Limits...
Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.

Shin S, Kim KJ, Cho IJ, Hong GR, Jang Y, Chung N, Rah YM, Chang HJ - Yonsei Med. J. (2015)

Bottom Line: We investigated whether triflusal use results in amelioration of PVD symptoms and improvement of several related parameters compared with aspirin.The use of triflusal resulted in a greater improvement in CISS score (44.5±18.4 vs. 51.9±16.2; p<0.001) and in mean radial peak systolic velocity (69.8±17.2 vs. 66.1±16.4; p=0.011) compared to aspirin.Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.

ABSTRACT

Purpose: Primary vascular dysregulation (PVD) is a condition in which the response to cold temperature or external stimuli is abnormal. We investigated whether triflusal use results in amelioration of PVD symptoms and improvement of several related parameters compared with aspirin.

Materials and methods: Eighty-eight PVD patients (54% female, 56±8 years) were randomly selected to receive either triflusal (300 mg, b.i.d.) or aspirin (150 mg, b.i.d.) for a period of 6 weeks followed by crossover. PVD was defined as both red-blood-cell standstill in video-assisted microscopic capillaroscopy during cold stimulation using carbon dioxide gas and a score of more than 7 points in a validated questionnaire. Efficacy of treatment was assessed by 1) cold intolerance symptom severity (CISS) score, 2) finger Doppler indices, and 3) indocyanine green perfusion imaging.

Results: The use of triflusal resulted in a greater improvement in CISS score (44.5±18.4 vs. 51.9±16.2; p<0.001) and in mean radial peak systolic velocity (69.8±17.2 vs. 66.1±16.4; p=0.011) compared to aspirin. Furthermore, significant differences were also observed in perfusion rates on indocyanine green perfusion imaging between triflusal and aspirin (45.6±25.8 vs. 51.6±26.9; p=0.020).

Conclusion: Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin.

Show MeSH

Related in: MedlinePlus

Study design. This study was a double-blind, randomized, crossover design. The selected patients were given either triflusal or aspirin for 6 weeks. After a washout period of 2 weeks, the drugs were crossed over, and the patients were given the drug they had not received for 6 more weeks. CISS, cold intolerance symptom severity; PSV, peak systolic velocity; ICG, indocyanine green.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4541651&req=5

Figure 1: Study design. This study was a double-blind, randomized, crossover design. The selected patients were given either triflusal or aspirin for 6 weeks. After a washout period of 2 weeks, the drugs were crossed over, and the patients were given the drug they had not received for 6 more weeks. CISS, cold intolerance symptom severity; PSV, peak systolic velocity; ICG, indocyanine green.

Mentions: This study proceeded in a double-blind, randomized, crossover design. Fig. 1 describes the overall process of the study. In short, the selected patients were given either triflusal (300 mg, b.i.d.) or aspirin (150 mg, b.i.d.) for 6 weeks. After a washout period of 2 weeks, the drugs were crossed over, and the patients were given the drug they had not originally received for 6 more weeks. During each 6-week period of drug administration, the patients' cold intolerance symptom severity (CISS) scores were measured, and finger Doppler and indocyanine green perfusion imaging were performed. Institutional Review Committee approval and informed consent were obtained, and all clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The ClinicalTrials.gov identifier was NCT01612273.


Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.

Shin S, Kim KJ, Cho IJ, Hong GR, Jang Y, Chung N, Rah YM, Chang HJ - Yonsei Med. J. (2015)

Study design. This study was a double-blind, randomized, crossover design. The selected patients were given either triflusal or aspirin for 6 weeks. After a washout period of 2 weeks, the drugs were crossed over, and the patients were given the drug they had not received for 6 more weeks. CISS, cold intolerance symptom severity; PSV, peak systolic velocity; ICG, indocyanine green.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4541651&req=5

Figure 1: Study design. This study was a double-blind, randomized, crossover design. The selected patients were given either triflusal or aspirin for 6 weeks. After a washout period of 2 weeks, the drugs were crossed over, and the patients were given the drug they had not received for 6 more weeks. CISS, cold intolerance symptom severity; PSV, peak systolic velocity; ICG, indocyanine green.
Mentions: This study proceeded in a double-blind, randomized, crossover design. Fig. 1 describes the overall process of the study. In short, the selected patients were given either triflusal (300 mg, b.i.d.) or aspirin (150 mg, b.i.d.) for 6 weeks. After a washout period of 2 weeks, the drugs were crossed over, and the patients were given the drug they had not originally received for 6 more weeks. During each 6-week period of drug administration, the patients' cold intolerance symptom severity (CISS) scores were measured, and finger Doppler and indocyanine green perfusion imaging were performed. Institutional Review Committee approval and informed consent were obtained, and all clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The ClinicalTrials.gov identifier was NCT01612273.

Bottom Line: We investigated whether triflusal use results in amelioration of PVD symptoms and improvement of several related parameters compared with aspirin.The use of triflusal resulted in a greater improvement in CISS score (44.5±18.4 vs. 51.9±16.2; p<0.001) and in mean radial peak systolic velocity (69.8±17.2 vs. 66.1±16.4; p=0.011) compared to aspirin.Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.

ABSTRACT

Purpose: Primary vascular dysregulation (PVD) is a condition in which the response to cold temperature or external stimuli is abnormal. We investigated whether triflusal use results in amelioration of PVD symptoms and improvement of several related parameters compared with aspirin.

Materials and methods: Eighty-eight PVD patients (54% female, 56±8 years) were randomly selected to receive either triflusal (300 mg, b.i.d.) or aspirin (150 mg, b.i.d.) for a period of 6 weeks followed by crossover. PVD was defined as both red-blood-cell standstill in video-assisted microscopic capillaroscopy during cold stimulation using carbon dioxide gas and a score of more than 7 points in a validated questionnaire. Efficacy of treatment was assessed by 1) cold intolerance symptom severity (CISS) score, 2) finger Doppler indices, and 3) indocyanine green perfusion imaging.

Results: The use of triflusal resulted in a greater improvement in CISS score (44.5±18.4 vs. 51.9±16.2; p<0.001) and in mean radial peak systolic velocity (69.8±17.2 vs. 66.1±16.4; p=0.011) compared to aspirin. Furthermore, significant differences were also observed in perfusion rates on indocyanine green perfusion imaging between triflusal and aspirin (45.6±25.8 vs. 51.6±26.9; p=0.020).

Conclusion: Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin.

Show MeSH
Related in: MedlinePlus